Completed PHASE2 INTERVENTIONAL 1-arm NCT02423980

G-Pen™ for Hypoglycemia Rescue in T1D Patients

G-Pen™ (Glucagon Injection) for Induced Hypoglycemia Rescue in Adult Patients With T1D

Sponsor: Xeris Pharmaceuticals

Interventions Glucagon

Updated 10 times since 2017 Last updated: Jun 7, 2017 Started: Apr 30, 2015 Primary completion: May 31, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hypoglycemia, this trial is completed. The trial is conducted by Xeris Pharmaceuticals and has accumulated 10 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Jun 2017 — Jul 2017 [monthly]

Completed PHASE2
Feb 2017 — Jun 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xeris Pharmaceuticals

Data source: Xeris Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Walnut Creek, United States